Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2) Jacques Cadranel, MD, PhD, Audrey Mauguen, MSc, Michele Faller, MD, PhD, Gérard Zalcman, MD, PhD, Marie-Pierre Buisine, PharmD, PhD, Virginie Westeel, MD, PhD, Elisabeth Longchampt, MD, Marie Wislez, MD, PhD, Bruno Coudert, MD, Catherine Daniel, MD, Bruno Chetaille, MD, Stephane Michiels, PhD, Helene Blons, MD, PhD, Jerome Solassol, MD, Florence De Fraipont, PharmD, PhD, Pascal Foucher, MD, Thierry Urban, MD, PhD, Ludovic Lacroix, MD, PhD, Virginie Poulot, LabTec, Elisabeth Quoix, MD, PhD, Martine Antoine, MD, Guillaume Danton, LabTec, Franck Morin, Ms, BSc, Christos Chouaid, MD, PhD, Jean-Pierre Pignon, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 10, Pages 1490-1502 (October 2012) DOI: 10.1097/JTO.0b013e318265b2b5 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 1 Flow chart. EGFR-TKI, epidermal growth factor tyrosine kinase inhibitor. Journal of Thoracic Oncology 2012 7, 1490-1502DOI: (10.1097/JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 2 Progression-free survival and overall survival curves for A, the clinical population (n = 522), and (B) biological population (n = 307). m, months. Journal of Thoracic Oncology 2012 7, 1490-1502DOI: (10.1097/JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 3 A, Progression-free survival and (B) overall survival curves by mutation status. m, months. Journal of Thoracic Oncology 2012 7, 1490-1502DOI: (10.1097/JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 4 A, Regression tree for PFS and (B) PFS curves corresponding to the four final groups of the regression tree. PFS, progression-free survival; PS, performance status; HR, hazards ratio; m, months. Journal of Thoracic Oncology 2012 7, 1490-1502DOI: (10.1097/JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 5 A, Regression tree for OS and (B) OS curves corresponding to the five final groups of the regression tree. PS, performance status; HR, hazards ratio; OS, overall survival; m, months. Journal of Thoracic Oncology 2012 7, 1490-1502DOI: (10.1097/JTO.0b013e318265b2b5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions